Last reviewed · How we verify
VIVITROL 380mg
At a glance
| Generic name | VIVITROL 380mg |
|---|---|
| Sponsor | Alkermes, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail (PHASE2, PHASE3)
- Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2) (PHASE2)
- Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults (PHASE4)
- Naltrexone for Overdose Prevention (PHASE2, PHASE3)
- Vivitrol Treatment for Cannabis Use Disorder (PHASE2)
- Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD (PHASE2)
- Emergency Department Initiated Extended-Release Naltrexone and Case Management for the Treatment of Alcohol Use Disorder (PHASE4)
- Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VIVITROL 380mg CI brief — competitive landscape report
- VIVITROL 380mg updates RSS · CI watch RSS
- Alkermes, Inc. portfolio CI